Page 271 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

250 PART III Therapeutic Modalities for the Cancer Patient

276. Serafini P, Meckel K, Kelso M, et al.: Phosphodiesterase-5 inhibition 280. Fernandez A, Mesa C, Marigo I, et al.: Inhibition of tumor-induced
augments endogenous antitumor immunity by reducing myeloid- myeloid-derived suppressor cell function by a nanoparticulated
derived suppressor cell function, J Exp Med 203(12):2691–2702, adjuvant, J Immunol 186(1):264–274, 2011.
VetBooks.ir 277. Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S: Generation of 281. Lathers DM, Clark JI, Achille NJ, Young MR: Phase 1B study to
2006.
improve immune responses in head and neck cancer patients using
antigen-presenting cells from tumor-infiltrated CD11b myeloid
nother 53(5):422–430, 2004.
cells with DNA demethylating agent 5-aza-2′-deoxycytidine, Can- escalating doses of 25-hydroxyvitamin D3, Cancer Immunol Immu-
cer Immunol Immunother 59(5):697–706, 2010. 282. Shojaei F, Singh M, Thompson JD, Ferrara N: Role of Bv8 in
278. Ko HJ, Lee JM, Kim YJ, et al.: Immunosuppressive myeloid-derived neutrophil-dependent angiogenesis in a transgenic model of cancer
suppressor cells can be converted into immunogenic APCs with the progression, Proc Natl Acad Sci U S A 105(7):2640–2645, 2008.
help of activated NKT cells: an alternative cell-based antitumor vac-
cine, J Immunol 182(4):1818–1828, 2009.
279. Pan PY, Wang GX, Yin B, et al.: Reversion of immune tolerance in
advanced malignancy: modulation of myeloid-derived suppressor
cell development by blockade of stem-cell factor function, Blood
111(1):219–228, 2008.